

Triumvira to Present Corporate Update at the 24th Annual Future Leaders in the Biotech Industry

HAMILTON, Ontario and HACKENSACK, NJ – April 3, 2017 – Triumvira Immunologics Inc. today announced that its President and Chief Executive Officer Tony Fiorino, MD, PhD, will present a corporate update at the 24th Annual Future Leaders in the Biotech Industry taking place on Friday, April 7 at the Millennium Broadway Hotel & Conference Center in New York. Triumvira is scheduled to present at 2:30 PM in Room 402/403.



About Triumvira Immunologics Inc.

Triumvira Immunologics Inc. is a biotechnology company developing a novel platform for engineering T cells to attack cancers. Triumvira's innovative and proprietary technology for reprogramming T cells, called the T Cell-Antigen Coupler (or TAC), may possess advantages over other approaches to engineered T cells owing to the distinct biology of TAC-T cells. In solid tumor models, TAC-T cells outperform Chimeric Antigen Receptor (CAR)-T cells, showing better efficacy and markedly improved on- and off-tumor toxicity that correlates with a modulated cytokine secretion profile. Triumvira has licensed the TAC technology from McMaster University in Hamilton, Ontario and intends to begin human testing of TAC T cells in 2018.

Contact

Triumvira Immunologics, Inc.
175 Longwood Road South, Suite 305
Hamilton, Ontario L8P 0A1, Canada
Phone: 1-201-882-4550
Email: info@triumvira.com